Síndrome intestino irritable

  • The gutmicrobiota in IBD.
    Manichanh C, Borruel N, Casellas F, Guarner F.
    NatRevGastroenterolHepatol. 2012 Oct; 9(10):599-608

  • Intestinal mucosal barrier function in health and disease .
    Turner JR.
    Nat Rev Immunol. 2009;9(11):799-809.

  • The intestinal barrier and its regulation by neuroimmune factors.
    Keita AV, Söderholm JD.
    Neurogastroenterol Motil 2010;22:718-33.

  • Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease.
    Blair SA, Kane SV, Clayburgh DR, Turner JR.
    Lab Invest. 2006;86(2):191-201.

  • A Crohn’s disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1.
    Noguchi E, Homma Y, Kang X, Netea MG, Ma X.
    Nat Immunol. 2009;10(5):471-9.

  • Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.
    Martínez C, Lobo B, Pigrau M, Ramos L, González-Castro AM, Alonso C, Guilarte M, Guilá M, de Torres I, Azpiroz F, Santos J, Vicario M.
    Gut. 2013;62(8):1160-8.

  • Impaired intestinal gas propulsion in manometrically proven dysmotility and in irritable bowel syndrome.
    Serra J, Villoria A, Azpiroz F, Lobo B, Santos J, Accarino A, Malagelada JR.
    Neurogastroenterol Motil 2010;22:401-402.

  • Randomised clinical trials: linaclotide phase 3 studies in IBS-C – a prespecified further analysis based on European Medicines Agency-specified endpoints.
    Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM.
    Aliment Pharmacol Ther 2013;37:49-61.

  • Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.
    Clave P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J.
    Aliment Pharmacol Ther 2011;34:432-442.

  • Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice — an evidence-based international guide.
    Hungin AP, Mulligan C, Pot B, Whorwell P, Agreus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Rubin G, Winchester C, de WN.
    Aliment Pharmacol Ther 2013;38:864-886.

  • Rifaximin therapy for patients with irritable bowel syndrome without constipation.
    Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP.
    N Engl J Med 2011;364:22-32.

  • A Diet low in FODMAPs reduces symptoms of Irritable Bowel Syndrome.
    Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG.
    Gastroenterology 2014;146(1):67-75.

  • For celiac disease, diagnosis is not enough.
    Gibson PR, Shepherd SJ, Tye-Din JA.
    Clin Gastroenterol Hepatol 2012;10:900-901.

  • An evidence-based position statement on the management of irritable bowel syndrome.
    Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM et al.
    Am J Gastroenterol 2009; 104 ( Suppl 1):S1–35.

  • Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation—a 12-week, randomized, double-blind, placebo-controlled study.
    Quigley EM, Vandeplassche L, Kerstens R, Ausma J.
    Aliment Pharmacol Ther 2009;29:315–28.

  • Randomised clinical trial: efficacy of linaclotide in patients with irritable bowel syndrome with constipation – an analysis of two double-blind, placebo-controlled phase 3 trials based on European Medicines Agency-specified endpoints.
    Quigley EMM TJ, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM.  
    Aliment Pharmacol Ther. 2013, Jan;37(1):49-61.

  • Síndrome del intestino irritable, enfermedad celiaca y gluten: una cosa es predicar y otra dar trigo.
    Mearin F, Montoro M.  
    Med Clin (en prensa).

  • Importancia de la dieta en el síndrome del intestino irritable.
    Mearin F, Peña E, Balboa A.  
    Gastroenterol Hepatol.(en prensa).

  • Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspectiva
    Tack J, Fried M, Houghton LA, Spicak J, Fisher G.
    Aliment Pharmacol Ther 2006; 24:183–205.

  • Review article: probiotics and prebiotics in irritable bowel syndrome
    Spiller R.
    Aliment Pharmacol Ther 2008; 28, 385–396.

  • An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. American College of Gastroenterology Task Force. on Irritable Bowel Syndrome
    Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EMM, Moayyedi P.
    Am J Gastroenterology 2009; 104:S1–S35.
  • Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis
    Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P.
    Gut 2009; 58:367–378.

  • Efficacy of tricyclic antidepressants in irritable bowel syndrome: A meta-analysis
    Rahimi R, Nikfar S, Rezaie A, Abdollahi M.
    World J Gastroenterol 2009; 15(13):1548-1553.
  • Probiotics in functional intestinal disorders and IBS: proof of action and dissecting the multiple mechanisms
    Marteau P.
    Gut 2010 59: 285-286.

  • Colonic Responses to Gas Loads in Subgroups of Patients With Abdominal Bloating
    Hernando-Harder AC, Serra J, Azpiroz F, Mil M, Aguadé S, Malagelada C, Tremolaterra F, Villoria A, Malagelada JR
    Am J Gastroenterol 2010; 105:876-882.

Estómago-Intestino | Permalink.

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

Aviso de cookies